NewAmsterdam Pharma Reports Positive Results from Phase 3 Trial of Obicetrapib
Key Findings:
Met Primary Endpoint:
The Phase 3 BROOKLYN clinical trial of obicetrapib showed a significant reduction in LDL-C levels compared to placebo. The mean reduction was 36.3% at day 84 and 41.5% at day 365.
Lp(a) Reduction:
Patients in the trial also experienced a reduction in Lp(a) levels, with a mean reduction of 45.9% at day 84 and 54.3% at day 365.
LDL-P Reduction:
Furthermore, there was a substantial reduction in total LDL-P levels compared to placebo, with a reduction of 52.5% at day 180. There was also a significant reduction in small LDL-P levels, with a reduction of 102.4%.
Safety Results:
The safety results from the trial were comparable to placebo, indicating that obicetrapib is well-tolerated by patients.
NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V., a biopharmaceutical company, announced these promising results from their Phase 3 trial of obicetrapib. The drug showed significant improvements in LDL-C, Lp(a), and LDL-P levels in patients with heterozygous familial hypercholesterolemia.
These findings provide hope for patients who have not responded well to existing therapies for cardiovascular disease.
How Will This Affect Me?
As a patient with heterozygous familial hypercholesterolemia, the results of the Phase 3 trial of obicetrapib are promising. If approved, this new drug could offer a more effective treatment option for managing your LDL-C levels.
How Will This Affect the World?
The development of obicetrapib represents a significant advancement in the treatment of cardiovascular disease. If approved, it could potentially benefit millions of patients worldwide who are struggling to control their LDL-C levels with current therapies.
Conclusion:
The positive results from the Phase 3 trial of obicetrapib are a significant milestone in the field of cardiovascular medicine. The potential approval of this drug could revolutionize the treatment of patients with heterozygous familial hypercholesterolemia and have a profound impact on the global effort to combat cardiovascular disease.
